1. Scrip
  2. >>Business
  3. >>Strategy

Biopharma Has Money To Spend On M&A, EY Says – As Well As Need

 
• By Joseph Haas

Upcoming patent expirations are increasing the sector’s need to acquire candidates and products that can deliver near-term revenues, driving up valuations, EY’s 2024 Firepower report says.

Firepower
The life sciences sector has $1.37tn to deploy in M&A, according to EY • Source: Shutterstock

The life sciences industry has significant capital it can deploy for mergers and acquisitions in 2024, with an estimated $1.37tn on hand, according to the EY M&A Firepower report released on 8 January. Combined with factors that should drive deep-pocketed biopharma companies to seek non-organic growth, EY anticipates a year of significant M&A activity in 2024, Arda Ural, one of the report’s authors, told Scrip.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By Mandy Jackson

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.

Amgen Under Pressure, But Seeing Gains Ahead Of Obesity Readouts

 
• By Mandy Jackson

MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.